Methods of otoprotection against platinum-based antineoplastic agents
Disclosed herein are methods for otoprotection against platinum-based antineoplastic agents by administering a thiosulfate salt to a subject in need thereof. Typically, the thiosulfate salt is administered to the subject scheduled to be administered a platinum-based antineoplastic agent within 4 hours. Alternatively, the thiosulfate salt is administered within 7 hours after the administration of a platinum-based neoplastic agent.
1. A method of mitigating platinum-induced hearing loss in a human subject in need thereof, the method comprising (i) administering to the subject by intratympanically or transtympanically injecting an effective amount of a hypertonic composition comprising 0.5M-1.0M of a thiosulfate salt, and (ii) intravenously administering cisplatin to the subject 1 to 3 hours following step (i).
2. The method of claim 1 , wherein the hypertonic composition comprises 1.0M of the thiosulfate salt.
3. The method of claim 1 , wherein the thiosulfate salt is sodium thiosulfate.
4. The method of claim 1 , wherein the hypertonic composition additionally comprises 1%-2% (w/v) of hyaluronan.
5. The method of claim 4 , wherein the hypertonic composition additionally comprises 1% (w/v) of hyaluronan.
6. The method of claim 1 , wherein the hypertonic composition is administered transtympanically.
7. The method of claim 6 , wherein the transtympanic administration is by injection directly through a tympanic membrane.
8. The method of claim 7 , wherein prior to injection a separate ventilation hole in the tympanic membrane is created to allow air to escape the middle ear space.
9. A method of mitigating platinum-induced hearing loss in a human subject in need thereof, the method comprising (i) administering to the subject by transtympanically injecting directly through a tympanic membrane an effective amount of a hypertonic composition comprising 1.0M of sodium thiosulfate and 1% (w/v) hyaluronan, and (ii) intravenously administering cisplatin to the subject 1 to 3 hours following step (i).
10. A method of mitigating platinum-induced hearing loss in a human subject in need thereof, the method comprising (i) creating a ventilation hole in the subject's tympanic membrane to allow air to escape the middle ear space upon transtympanic administration of a composition; (ii) administering to the subject by transtympanically injecting directly through the tympanic membrane an effective amount of a hypertonic composition comprising 1.0M of sodium thiosulfate and 1% (w/v) hyaluronan; and (iii) intravenously administering cisplatin to the subject 1 to 3 hours following step (ii).